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Abstract
Among 249 patients with teratoma-associated encephalitis, 211 had N-methyl-D-aspartate receptor 
antibodies and 38 were negative for these antibodies. Whereas antibody-positive patients rarely 
developed prominent brainstem–cerebellar symptoms, 22 (58%) antibody-negative patients 
developed a brainstem–cerebellar syndrome, which in 45% occurred with opsoclonus. The median 
age of these patients was 28.5 years (range = 12–41), 91% were women, and 74% had full 
recovery after therapy and tumor resection. These findings uncover a novel phenotype of 
paraneoplastic opsoclonus that until recently was likely considered idiopathic or postinfectious. 
The triad of young age (teenager to young adult), systemic teratoma, and high response to 
treatment characterize this novel brain-stem–cerebellar syndrome.
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The discovery of anti–N-methyl-D-aspartate receptor (NMDAR) encephalitis in 20071 has 
brought attention to a relationship between systemic teratomas and autoimmune 
encephalitis. Since 2007, we have studied 249 patients with teratoma-associated 
encephalitis; most of these patients had antibodies against the NR1 subunit of the NMDAR, 
but 38 were NMDAR antibody negative. When these 38 patients were compared with those 
with NMDAR antibodies, a novel brainstem–cerebellar syndrome that frequently associates 
with opsoclonus emerged. The current study describes the clinical differences between 
NMDAR antibody-positive and antibody-negative patients with systemic teratoma, and 
focuses on the novel brainstem–cerebellar syndrome and the subgroup of patients with 
opsoclonus.
Patients and Methods
From January 2007 until September 2012, serum and CSF of 249 patients with teratoma-
associated encephalitis were studied at the Department of Neurology, Hospital of the 
University of Pennsylvania and at the Neurology Service, Hospital Clinic, August Pi i 
Sunyer Biomedical Research Institute, University of Barcelona. The presence of a systemic 
teratoma was confirmed pathologically in 234 patients and radiologically in 15. Information 
was obtained by the authors or provided by referring physicians at symptom onset and at 
regular intervals during the course of the disease using a comprehensive questionnaire that 
includes all symptoms shown in the Figure.2 Sera and cerebrospinal fluid (CSF) were 
examined for antibodies to NMDA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic 
acid, γ-aminobutyric acid (B), and mGluR5 receptors, LGI1, Caspr2, onconeuronal proteins 
(Hu, CRMP5, Ma1–2, amphiphysin), and GAD65, using reported techniques including brain 
immunohistochemistry, immunoblot, and cell-based assays.3–5 Patients without NMDAR 
antibodies were further studied for antibodies to dipeptidyl-peptidase-like protein-6 (DPPX), 
α1-glycine receptor, D2 subunit of the dopamine receptor, and unknown cell-surface 
antigens using reported techniques.3–5
Outcome was assessed with the modified Rankin scale (mRS),6 grading it as full recovery 
(mRS = 0), substantial improvement (mRS = 1–2), partial improvement (mRS > 2 after 
having had at least 1 point of improvement), and no improvement. Three patients without 
NMDAR antibodies have been previously reported.7–9 Studies were approved by the internal 
review boards of the University of Pennsylvania and University of Barcelona.
Statistical Analysis
Comparative analyses between patients with and without NMDAR antibodies were 
performed with SPSS version 20 (IBM, Armonk, NY), using the Fisher exact test for 
contingency tables and Mann–Whitney U tests for continuous variables.
Results
Two hundred eleven patients were found to have NMDAR antibodies, and 38 were negative 
for these antibodies. Compared with antibody-positive patients, the 38 patients without 
NMDAR antibodies showed no differences with respect to gender and age of symptom onset 
(NMDAR antibody-negative patients: 92% female, median age = 28 years [interquartile 
Armangue et al. Page 2













range (IQR) = 20–32, range = 12–55] vs antibody-positive patients: 99% female, median age 
= 25 years [IQR = 19–30, range = 7–65], p = 0.05 and p = 0.11, respectively). However, 
significant differences were identified with respect to symptom presentation and repertoire 
of symptoms during the first month of the disease (see Fig 1). Whereas 18 (47%) patients 
without NMDAR antibodies initially presented with brainstem–cerebellar dysfunction, this 
presentation did not occur in any of the patients with NMDAR antibodies (p < 0.0005). In 
contrast, whereas 144 of 211 (68%) patients with NMDAR antibodies presented with 
psychosis and behavioral abnormalities, this presentation occurred only in 4 of 38 (11%) 
patients without these antibodies (p < 0.0005).
The Figure shows that during the first month of the disease, 76% of the patients with 
NMDAR antibodies developed dyskinesias, often involving the face and mouth, whereas 
only 1 (3%) patient without these antibodies developed dyskinesias, without affecting the 
face and mouth (p < 0.0005); similar differences were seen for most symptoms typical of 
anti-NMDAR encephalitis. In contrast, 22 of 38 (58%) patients without NMDAR antibodies 
developed brainstem–cerebellar symptoms during the first month of the disease, 10 (45%) of 
them with opsoclonus, whereas these symptoms rarely occurred in patients with NMDAR 
antibodies. The identification of a predominant brainstem–cerebellar syndrome led us to 
focus on this disorder and the subgroup of patients with opsoclonus, both described below 
(the other 16 patients are shown in the Supplementary Table).
Brainstem–Cerebellar Syndrome
The median age of the 22 patients with brainstem–cerebellar symptoms was 28.5 years (IQR 
= 22–32, range = 12–41). Twenty (91%) were female, all with ovarian teratoma; 2 male 
patients had testicular teratoma. Main symptoms included ataxia in 86%, opsoclonus–
myoclonus in 45% (described below), dysarthria in 36%, decreased level of consciousness in 
32%, diplopia or ophthalmoparesis in 18%, and seizures in 18%. Other symptoms are listed 
in the Table 1.
Neurological symptoms developed before tumor diagnosis in 18 patients (82%; median = 1 
month, IQR = 0.9–2 months, range = 3 days to 24 months) and after tumor diagnosis in 4 
(10 days and 1.5, 2, and 3.5 months, respectively). Two of these 4 patients had the tumor 
removed 3 days and 1.5 months before developing encephalitis, respectively. All patients 
had mature teratomas, except 1 who had an immature ovarian teratoma. Serum of 3 patients 
(2 with opsoclonus) and CSF of another patient showed weak immunolabeling of cultures of 
rat neurons (data not shown); no antibodies were identified in the other patients.
Treatment and follow-up information was available for 19 (86%) patients, including all 
patients with opsoclonus (described below). Fifteen (79%) received immunotherapy, 13 of 
them with tumor resection; 2 had tumor resection without immunotherapy, and 2 were not 
treated (1 had tumor removal before developing encephalitis). With a median follow-up of 
15 months (range = 3–84), 14 patients (74%) had full recovery, 3 (16%) had partial 
improvement, and 2 had no improvement (1 of them was not treated). Two patients with 
complete recovery and 1 with partial recovery relapsed 2 years, 7 years, and 8 months after 
disease onset, respectively.
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Ten women (median age = 27 years, IQR = 22–30, range = 15–32) with brainstem–
cerebellar syndrome developed opsoclonus; accompanying symptoms are listed in the Table 
1. Four had prodromal fever or viral-like symptoms, and another one was 26 weeks 
pregnant. Symptoms developed before the tumor diagnosis in 7 (median = 1 month, IQR = 
0.1–1.5 months, range = 3 days to 2 months) and after tumor diagnosis in 3 (10 days, 2 
months, and 3.5 months, respectively). One of these 3 patients had undergone tumor 
resection 3 days before developing opsoclonus; the other 2 patients had not had tumor 
treatment.
At symptom onset, 7 patients had CSF lymphocytic pleocytosis (median = 37 white blood 
cells/μl, range = 10–182), 6 had increased protein concentration (median 5= 64/dl, range 49–
100), and 3 of 3 had oligoclonal bands. Brain magnetic resonance imaging and 
electroencephalographic studies were abnormal in 2 of 9 and 3 of 5 patients (see Table 1).
All patients were treated with methylprednisolone: 3 alone, 3 combined with intravenous 
immunoglobulin (IVIg), and 4 with IVIg and plasma exchange. Two patients received 
rituximab after failing initial immunotherapy, and 1 received azathioprine (see Table 1). 
Nine patients had resection of the teratoma; pathological studies showed mature teratoma in 
8, including 1 with bilateral teratomas, and immature teratoma in 1. Chemotherapy was used 
in 2 patients (see Table 1). Valproic acid, clonazepam, levetiracetam, or phenobarbital did 
not control the opsoclonus–myoclonus (data not shown).
The median time of follow-up was 19.5 months (IQR = 6–39, range = 3–84). Eight patients 
had full recovery, and 2 had mild residual dysarthria and ataxia at 13- and 15-month follow-
up, respectively. Six of the 8 patients with full recovery became asymptomatic within the 
first 3 months of treatment, and the other 2 patients within 6 and 12 months, respectively.
Discussion
This study shows that patients with systemic teratoma can develop several forms of 
encephalitis without NMDAR antibodies, among which a syndrome that associates with 
brainstem–cerebellar symptoms stands out. Almost 50% of patients with this syndrome 
developed opsoclonus in association with the triad of young age (teenager to young adult), 
presence of an ovarian teratoma, and high response to treatment. The subacute presentation 
of symptoms, frequent CSF pleocytosis, and response to immunotherapy coupled with the 
detection of antibodies to neuronal cell-surface antigens in some patients suggest an 
immune-mediated pathogenesis.
All patients with opsoclonus were young women (aged 15–32 years), considered too young 
for carcinoma-associated opsoclonus, which usually occurs in patients >50 years old,10 and 
too old for neuroblastoma-associated opsoclonus, which usually affects children <5 years 
old.11 It is likely that this type of opsoclonus has been previously considered idiopathic or 
postinfectious and that the presence of a teratoma was missed or not felt to be related.
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Compared with patients with anti-NMDAR encephalitis, those without these antibodies were 
less likely to initially present with psychosis and behavioral change. Although there was 
overlap of some symptoms, such as limbic dysfunction and psychiatric manifestations, the 
frequency of other symptoms, such as dyskinesias, rarely occurred in patients without 
NMDAR antibodies. In contrast, patients with anti-NMDAR encephalitis did not initially 
present with brainstem–cerebellar dysfunction or opsoclonus. Of note, ataxia can be a 
presentation of anti-NMDAR encephalitis in children2,12; this is not reflected here, because 
young children usually do not have teratomas.
This study has several practical implications. Any teenager or young adult, especially if 
female, who develops subacute brainstem–cerebellar symptoms or opsoclonus–myoclonus 
suspected to be immune-mediated (because of the rapid onset of symptoms and/or CSF 
pleocytosis) should be investigated for a teratoma in the ovary (or testes for male patients). 
Detection of a teratoma should prompt its removal along with the use of immunotherapy 
(most patients described here received steroids, IVIg, and/or plasma exchange). A limitation 
of this study is that it is retrospective; future studies will establish the frequency of these 
disorders and may identify patients with higher levels of cell-surface antibodies that could 
lead to the characterization of the antigens.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Comparison of symptoms of patients with teratoma-associated encephalitis and N-methyl-D-
aspartate receptor (NMDAR) antibodies with those without NMDAR antibodies. (A) 
Patients without NMDAR antibodies (indicated in dark gray) less frequently developed 
symptoms considered characteristic of anti-NMDAR encephalitis (behavioral abnormalities, 
memory deficits, seizures, dyskinesias, speech disorder, and central hypoventilation, all p < 
0.0005, and impaired level of consciousness and autonomic dysfunction, p < 0.05). (B) In 
addition, patients without NMDAR antibodies more frequently developed brain-stem–
cerebellar symptoms and opsoclonus, which are rare in anti-NMDAR encephalitis (all p < 
0.0005). From 1 patient without NMDAR antibodies and 4 with antibodies, detailed clinical 
information was not available, and these patients were excluded from analysis; in 3 
additional patients without NMDAR antibodies, information for memory deficits and speech 
disorder was not available.
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